AC Immune (ACIU) Assets Average (2016 - 2026)
AC Immune (ACIU) posted quarterly Assets Average of $87.8 billion for Q1 2026, up 35151.09% year-over-year from N/an in Q1 2025, and up 43009.42% quarter-over-quarter from $203.8 million in Q4 2025.
AC Immune (ACIU) Assets Average (2016 - 2026) Analysis & Trends
AC Immune (ACIU) has reported Assets Average for 10 consecutive years, with $87.8 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 35151.09% year-over-year to $87.8 billion; the TTM figure through Mar 2026 stood at $87.8 billion (up 35151.09% YoY), while the FY2025 annual figure was $224.8 million, down 4.27% from the prior year.
- Assets Average grew to $87.8 billion in Q1 2026 per ACIU's latest filing, from $203.8 million in the prior quarter.
- Across five years, Assets Average topped out at $87.8 billion in Q1 2026 and bottomed at $240054.7 in Q2 2022.
- Historically, Assets Average has averaged $5.3 billion across 5 years, with a median of $202.9 million in 2022.
- Annual changes were most pronounced in 2023 — Assets Average jumped 74181.33% — and 2025, when it fell 25.29%.
- AC Immune's Assets Average stood at $202.9 million in 2022, then declined by 9.33% to $184.0 million in 2023, then soared by 48.24% to $272.8 million in 2024, then declined by 25.29% to $203.8 million in 2025, then surged by 43009.42% to $87.8 billion in 2026.
- Business Quant data shows ACIU's Assets Average at $87.8 billion in Q1 2026, $203.8 million in Q4 2025, and $222.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | AC Immune | 253.89 Mn | 253.89 Mn | - | 87.84 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 87.84 Bn |
| Mar 31, 2026 | 87.84 Bn |
| Dec 31, 2025 | 203.76 Mn |
| Sep 30, 2025 | 222.15 Mn |
| Jun 30, 2025 | 232.27 Mn |
| Mar 31, 2025 | 249.18 Mn |
| Dec 31, 2024 | 272.75 Mn |
| Sep 30, 2024 | 272.29 Mn |
| Jun 30, 2024 | 227.16 Mn |
| Mar 31, 2024 | 198.87 Mn |
| Dec 31, 2023 | 183.99 Mn |
| Sep 30, 2023 | 167.82 Mn |
| Jun 30, 2023 | 178.32 Mn |
| Mar 31, 2023 | 187.94 Mn |
| Dec 31, 2022 | 202.93 Mn |
| Sep 30, 2022 | 106.54 Mn |
| Jun 30, 2022 | 240,054.67 |
| Mar 31, 2022 | 141.90 Mn |
| Dec 31, 2021 | 141.88 Mn |
| Sep 30, 2021 | 226,507.87 |